Furthermore, we identified histone methyltransferase G9a as a key epigenetic regulator of autophagy and suggested that G9a could act as a potential therapeutic target in NAFLD. The gene discussed is PRDM9; the disease is metabolic dysfunction-associated steatotic liver disease.